These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21913874)

  • 21. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development.
    Vudattu NK; Herold KC
    Expert Opin Biol Ther; 2014 Mar; 14(3):377-85. PubMed ID: 24517093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression?
    Schatz D; Cuthbertson D; Atkinson M; Salzler MC; Winter W; Muir A; Silverstein J; Cook R; Maclaren N; She JX; Greenbaum C; Krischer J
    Pediatr Diabetes; 2004 Jun; 5(2):72-9. PubMed ID: 15189492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-CD3 monoclonal antibodies for the prevention and treatment of type 1 diabetes: A literature review.
    LeFevre JD; Cyriac SL; Tokmic A; Pitlick JM
    Am J Health Syst Pharm; 2022 Nov; 79(23):2099-2117. PubMed ID: 36056809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial.
    Füchtenbusch M; Rabl W; Grassl B; Bachmann W; Standl E; Ziegler AG
    Diabetologia; 1998 May; 41(5):536-41. PubMed ID: 9628270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Unitarian Hypothesis for the aetiology of diabetes mellitus.
    Morrison EY; Ragoobirsingh D; Peter SA
    Med Hypotheses; 2006; 67(5):1115-20. PubMed ID: 16806731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subcutaneous Administration of Otelixizumab is Limited by Injection Site Reactions: Results of an Exploratory Study in Type 1 Diabetes Mellitus Patients.
    MacDonald A; Ambery P; Donaldson J; Hicks K; Keymeulen B; Parkin J
    Exp Clin Endocrinol Diabetes; 2016 May; 124(5):288-93. PubMed ID: 27023009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can we prevent type 1 diabetes?
    Chalew SA
    J La State Med Soc; 2000 Jun; 152(6):286-8. PubMed ID: 10935367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suggested insulin regimens for patients with type 1 diabetes mellitus who wish to fast during the month of Ramadan.
    Kobeissy A; Zantout MS; Azar ST
    Clin Ther; 2008 Aug; 30(8):1408-15. PubMed ID: 18803984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-CD3 Antibody for the Prevention of Type 1 Diabetes: A Story of Perseverance.
    Gaglia J; Kissler S
    Biochemistry; 2019 Oct; 58(40):4107-4111. PubMed ID: 31523950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity.
    Taylor JR; Dietrich E; Powell JG
    Clin Ther; 2013 Jan; 35(1):A3-17. PubMed ID: 23328274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes.
    Mignogna C; Maddaloni E; D'Onofrio L; Buzzetti R
    Expert Opin Investig Drugs; 2021 Dec; 30(12):1209-1219. PubMed ID: 34936848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual β-cell function in new-onset type 1 diabetes mellitus.
    Gabbay MA; Sato MN; Finazzo C; Duarte AJ; Dib SA
    Arch Pediatr Adolesc Med; 2012 Jul; 166(7):601-7. PubMed ID: 22751874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-CD3 monoclonal antibody treatment in newly diagnosed Type 1 diabetes patients: a hypothetical modelling analysis.
    Smith-Palmer J; Curtis BH; Boye KS; Goodall G; Pillemer SR
    Diabet Med; 2010 Feb; 27(2):189-96. PubMed ID: 20546263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD3 antibody treatment stimulates the functional capability of regulatory T cells.
    Chatenoud L
    Novartis Found Symp; 2003; 252():279-86; discussion 286-90. PubMed ID: 14609225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patients.
    Vlasakakis G; Napolitano A; Barnard R; Brown K; Bullman J; Inman D; Keymeulen B; Lanham D; Leirens Q; MacDonald A; Mezzalana E; Page K; Patel M; Savage CO; Zamuner S; van Maurik A
    Br J Clin Pharmacol; 2019 Apr; 85(4):704-714. PubMed ID: 30566758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prevention of diabetes mellitus type 1].
    Scherbaum WA; Hauner H
    Dtsch Med Wochenschr; 2005 Jan; 130(4):141-2. PubMed ID: 15662579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention and reversal of type 1 diabetes--past challenges and future opportunities.
    Skyler JS
    Diabetes Care; 2015 Jun; 38(6):997-1007. PubMed ID: 25998292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Type 1 diabetes mellitus: primary, secondary, and tertiary prevention.
    Bollyky J; Sanda S; Greenbaum CJ
    Mt Sinai J Med; 2008 Aug; 75(4):385-97. PubMed ID: 18729155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of type 1 diabetes.
    Wherrett DK; Daneman D
    Pediatr Clin North Am; 2011 Oct; 58(5):1257-70, xi. PubMed ID: 21981959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.